Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Bayer now present in four of the largest biotechnology hubs in the United States
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)